India’s leading drugmaker Glenmark Pharmaceuticals Limited has announced that its US subsidiary, Glenmark Pharmaceuticals Inc. (GPI), has launched Nabumetone tablets and Hydroxyzine Hydrochloride tablets in the U.S. market.

Nabumetone is a non-steroidal anti-inflammatory drug, which is used to treat pain or inflammation caused by arthritis. While Hydroxyzine belongs to a group of medicines called sedating antihistamines and it is used in the treatment of anxiety.

Under the deal, Glenmark will exclusively market and distribute Nabumetone and Hydroxyzine Hydrochloride tablets while InvaGen will be responsible for their manufacture and supply.

The development, regulatory costs and profits on these two tablets’ sale in the US will be shared equally between Glenmark and Invagen.

This recent approval expands Glenmark's portfolio to 28 generic products for the US market. The Company has over 35 ANDAs undergoing review with the US FDA for approval / launch.